Is AbbVie About to Deliver a Blow to Gilead Sciences' Guidance?
After boosting its full-year hepatitis C revenue guidance last month, Gilead Sciences' (NASDAQ: GILD) share price has been rallying. However, the Food and Drug Administration approved AbbVie's (NYSE: ABBV) next-generation hepatitis C drug Mavyret this week, and AbbVie has priced it to sell. Could Mavyret deliver a big blow to Gilead Sciences' hopes for higher hepatitis C sales?
Hepatitis C treatment has taken big steps forward over the past decade. Previous treatments including the side effect-causing drugs peg interferon and ribavirin have been replaced by next-generation drugs that deliver functional cure rates that are above 90% in as few as 12 weeks, and in some patients, as little as eight weeks.
IMAGE SOURCE: GETTY IMAGES.
Source: Fool.com
Gilead Sciences Inc Stock
Gilead Sciences Inc is currently one of the favorites of our community with 11 Buy predictions and no Sell predictions.
With a target price of 85 € there is a slightly positive potential of 19.68% for Gilead Sciences Inc compared to the current price of 71.02 €.
